System for determining unprocessed and partially processed neurotoxin type A
AssigneeMERZ PHARMA GmbH & CO. KGaA
InventorsHarold Victor Taylor, Karl-Heinz Eisele, Cornelia Brunn
Life of this patent
Estimating the term…
Loading patent…
AssigneeMERZ PHARMA GmbH & CO. KGaA
InventorsHarold Victor Taylor, Karl-Heinz Eisele, Cornelia Brunn
Estimating the term…
The present invention is concerned with tools for the quality control and safety during manufacture of neurotoxins. In particular, it relates to a method for the determination of the amount of partially processed and/or unprocessed Botulinum neurotoxin A polypeptide (BoNT/A) in a solution comprising processed and partially processed and/or unprocessed BoNT/A comprising the steps of contacting a sample of the solution with a capture antibody which specifically binds to the partially processed and unprocessed BoNT/A under conditions which allow for binding of the antibody to the partially processed and unprocessed BoNT/A, whereby a complex is formed, and determining the amount of the formed complex, whereby the amount of the complex is indicative for the amount of the partially processed and/or unprocessed BoNT/A in the solution. Moreover, the present invention contemplates a device and a kit for carrying out the method.
A method for determining an amount of partially processed and/or unprocessed Clostridium botulinum neurotoxin A (BoNT/A) in a solution comprising processed and partially processed and/or unprocessed BoNT/A, wherein the partially processed and unprocessed BoNT/A exhibit a linker peptide, comprising the steps of:
Dependencies are inferred from the claim text.